Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021148 | 0.83 | ADRA1A (0.50) | ADRA1A | |
| SCHEMBL7246237 | 0.78 | NCF1 (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL11312898 | 0.71 | CHRNE (0.41) | S1PR1CHRNE | |
| SCHEMBL16286838 | 0.69 | S1PR1 (0.33) | S1PR1 | |
| SCHEMBL4823275 | 0.66 | ADRA1A (0.33) | CYP11B1CYP11B2ADRA1A | |
| SCHEMBL5021141 | 0.64 | ACHE (0.40) | ADRA1A | |
| SCHEMBL24133301 | 0.63 | BCL2L1 (0.38) | CHRNE | |
| SCHEMBL14425202 | 0.63 | RXRG (0.38) | S1PR1CHRNE | |
| SCHEMBL10273805 | 0.62 | S1PR1 (0.48) | S1PR1CHRNE | |
| SCHEMBL21955093 | 0.62 | HTR2C (0.32) | CHRNE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | S1PR1 1517/4885CYP11B1 899/4885CYP11B2 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.